Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of Phase 1 and Phase 3 MANEUVER trial data

Gelderblom H, et al. | 358P

Adverse events and their management in patients with tenosynovial giant cell tumor treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial

Ravi V, et al. | 361P

Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): results from the Phase 3 MANEUVER trial

Tinoco G, et al. | 357P

Precemtabart tocentecan (Precem-TcT), an anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic pancreatic ductal carcinoma (mPDAC): results from the Phase 1b/2 PROCEADE^®-PanTumor PDAC substudy

Wainberg Z, et al. | 182P

Indirect comparison of the effectiveness of tepotinib and immunotherapy in NSCLC with METex14 skipping alterations: Final propensity-scored analysis of eight pooled real-world datasets (TOGETHER) vs the VISION trial.

Guisier F, et al. | e20751

Comparative effectiveness in METex14 NSCLC: Outcomes from a propensity score–based analysis of 8 pooled real-world datasets (the TOGETHER study).

Greillier L, et al. | e20749

Profiling patients with MET exon 14 (METex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION

Paik P, et al. | 402P

Survival and treatment patterns of patients with metastatic urothelial cancer in France: results of a cohort study using the French National Healthcare database (SNDS)

Barthélémy P, et al. | 89P

Avelumab + sacituzumab govitecan vs avelumab monotherapy as first-line maintenance treatment for advanced urothelial carcinoma: updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites

Grivas P, et al. | 47P

Shared treatment decision-making between physicians and their patients with metastatic urothelial carcinoma: results of a real-world survey in Europe and the United States

Kearney M. | e16581

Outcomes with first-line platinum-based chemotherapy and avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma by NECTIN4 and HER2 RNA expression: Exploratory analyses from JAVELIN BLADDER 100

Klümper N, et al. | 54P

Individualizing first-line treatment choices in metastatic urothelial carcinoma (mUC): Results from a cross-sectional study of physicians in Europe

Unsworth M. | e16579